Assembly Biosciences, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Assembly Biosciences, Inc. (ASMB) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $7.36 million as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-19
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.36M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.08M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $9.95M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $9.92M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $7.36M 10-K · filed 2026-03-19 |
| 2024-12-31 | $7.08M 10-K · filed 2026-03-19 |
| 2023-12-31 | $9.95M 10-K · filed 2025-03-20 |
| 2022-12-31 | $9.92M 10-K · filed 2024-03-28 |
| 2021-12-31 | $11.08M 10-K · filed 2023-03-22 |
| 2020-12-31 | $16.56M 10-K · filed 2022-03-11 |
| 2019-12-31 | $12.35M 10-K · filed 2021-02-25 |
| 2018-12-31 | $14.02M 10-K · filed 2020-03-04 |
| 2017-12-31 | $5.73M 10-K · filed 2019-02-28 |
| 2016-12-31 | $9.28M 10-K · filed 2018-03-08 |
| 2015-12-31 | $10.40M 10-K · filed 2017-03-02 |
| 2014-12-31 | $11.69M 10-K · filed 2016-03-11 |
| 2013-12-31 | $6.62M 10-K · filed 2015-03-16 |
| 2012-12-31 | $5.81M 10-K · filed 2014-03-31 |
| 2011-12-31 | $4.40M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |